|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Early prediction of major depression in chronic hepatitis C patients during peg-interferon α-2b treatment by assessment of vegetative-depressive symptoms after four weeks显示文摘AIM: To study the predictive value of the vegetative- depressive symptoms of the Zung Depression Rating Scale for the occurrence of depression during treatment with peg-interferon α-2b of chronic hepatitis C (CHC) patients. METHODS: The predictive value of vegetative- depressive symptoms at 4 wk of treatment for the occurrence of a subsequent diagnosis of major depressive disorder (MDD) was studied in CHC patients infected after substance use in a prospective, multi- center treatment trial in Belgium. The presence of vegetative-depressive symptoms was assessed using the Zung Scale before and 4 wk after the start of antiviral treatment. RESULTS: Out of 49 eligible patients, 19 (39%) developed MDD. The area under the ROC curve of the vegetative Zung subscale was 0.73, P = 0.004. The sensitivity at a cut-point of > 15/35 was 95% (95% CI: 74-100). The positive predictive value equalled 44% (95% CI: 29-60). CONCLUSION: In this group of Belgian CHC patients infected after substance use, antiviral treatment caused a considerable risk of depression. Seven vegetativedepressive symptoms of the Zung scale at wk 4 of treatment predicted 95% of all emerging depressions, at a price of 56% false positive test results. | Geert Robaeys Jozef De Bie Marieke C Wichers Liesbeth Bruckers Frederik Nevens Peter Michielsen Marc Van Ranst Frank Buntinx | 2007 | World Journal of Gastroenterology2007，13，43： | 4 |
| 2 | Recommendations for the Management of Hepatitis C Virus Infection Among People Who Inject Drugs显示文摘 | Geert Robaeys Jason Grebely Stefan Mauss Philip Bruggmann Joseph Moussalli Andrea De Gottardi Tracy Swan Amber Arain Achim Kautz Heino St?ver Heiner Wedemeyer Martin Schaefer Lynn Taylor Markus Backmund Olav Dalgard Maria Prins Gregory J. Dore | 2013 | Clinical Infectious Diseases . 2013 (supp)2013，，： | 1 |
| 3 | Recommendations for the Management of Hepatitis C Virus Infection Among People Who Inject Drugs显示文摘 | Geert Robaeys Jason Grebely Stefan Mauss Philip Bruggmann Joseph Moussalli Andrea De Gottardi Tracy Swan Amber Arain Achim Kautz Heino St?ver Heiner Wedemeyer Martin Schaefer Lynn Taylor Markus Backmund Olav Dalgard Maria Prins Gregory J. Dore | 2013 | Clinical Infectious Diseases (suppl )2013，，2： | 1 |
| 4 | Eligibility of persons who inject drugs for treatment of hepatitis C virus infection显示文摘In this decade, an increase is expected in end-stageliver disease and hepatocellular carcinoma, most commonly caused by hepatitis C virus(HCV) infection.Although people who inject drugs(PWID) are the ma-jor source for HCV infection, they were excluded fromantiviral treatments until recently. Nowadays there isincontrovertible evidence in favor of treating these patients, and substitution therapy and active substanceuse are no longer contraindications for antiviral treatment. The viral clearance in PWID after HCV antiviraltreatment with interferon or pegylated interferon combined with ribavirin is comparable to the viral clearancein non-substance users. Furthermore, multidisciplinary approaches to delivering treatment to PWID are advised, and their treatment should be considered on anindividualized basis. To prevent the spread of HCV inthe PWID community, recent active PWID are eligiblefor treatment in combination with needle exchange programs and substitution therapy. As the rate of HCV reinfection is low after HCV antiviral treatment, there is no need to withhold HCV treatment due to concerns about reinfection alone. Despite the advances in treatment efficacies and data supporting their success, HCV assessment of PWID and initiation of antiviral treatment remains low. However, the proportion of PWID assessed and treated for HCV is increasing, which can be further enhanced by understanding the barriers to and facilitators of HCV care. Removing stigmatization and implementing peer support and group treatment strategies, in conjunction with greater involvement by nurse educators/practitioners, will promote greater treatment seeking and adherence by PWID. Moreover, screening can be facilitated by noninvasive methods for detecting HCV antibodies and assessing liver fibrosis stages. Recently, HCV clearance has become a major endpoint in the war against drugs for the Global Commission on Drug Policy. This review highlights the most recent evidence concerning HCV infection and treatment strategies in PWID. | Amber Arain Geert Robaeys | 2014 | World Journal of Gastroenterology2014，20，36： | 1 |
| 5 | Recommendations for the Management of Hepatitis C Virus Infection Among People Who Inject Drugs显示文摘 | Geert Robaeys Jason Grebely Stefan Mauss Philip Bruggmann Joseph Moussalli Andrea De Gottardi Tracy Swan Amber Arain Achim Kautz Heino St?ver Heiner Wedemeyer Martin Schaefer Lynn Taylor Markus Backmund Olav Dalgard Maria Prins Gregory J. Dore | 2013 | Clinical Infectious Diseases (suppl )2013，，2： | 1 |
| 6 | Hepatitis C infection, antiviral treatment and mental health: A European expert consensus statement显示文摘 | Martin Schaefer Lucile Capuron Astrid Friebe Crisanto Diez-Quevedo Geert Robaeys Sergio Neri Graham R. Foster Achim Kautz Daniel Forton Carmine M. Pariante | 2012 | Journal of Hepatology2012，，6： | 1 |
| 7 | Hepatitis B virus and hepatitis C virus infections in Belgium: similarities and differences in epidemics and initial management显示文摘 | Bénédicte De Vroey Christophe Moreno Wim Laleman Marc van Gossum Isabelle Colle Chantal de Galocsy Philippe Langlet Geert Robaeys Hans Orlent Peter Michielsen Jean Delwaide Hendrik Reynaert Fran?ois D’Heygere Dirk Sprengers Stefan Bourgeois Collins Assene | 2013 | European Journal of Gastroenterology & Hepatology2013，，5： | 1 |
| 8 | Hepatitis C infection, antiviral treatment and mental health: A European expert consensus statement显示文摘 | Martin Schaefer Lucile Capuron Astrid Friebe Crisanto Diez-Quevedo Geert Robaeys Sergio Neri Graham R. Foster Achim Kautz Daniel Forton Carmine M. Pariante | 2012 | Journal of Hepatology2012，，6： | 1 |
| 9 | An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment显示文摘During treatment of chronic hepatitis C patients with interferon and ribavirin, a lot of side effects are described. Twenty-three percent to 44% of patients develop depression. A minority of patients evolve to psychosis. To the best of our knowledge, no cases of psychogenic parasitosis occurring during interferon therapy have been described in the literature. We present a 49-year-old woman who developed a delusional parasitosis during treatment with pegylated interferon alpha-2b weekly and ribavirin. She complained of seeing parasites and the larvae of fleas in her stools. This could not be confirmed by any technical examination. All the complaints disappeared after stopping pegylated interferon alpha-2b and reappeared after restarting it. She had a complete sustained viral response. | Geert Robaeys Jozef De Bie Marc Van Ranst Frank Buntinx | 2007 | World Journal of Gastroenterology2007，13，16： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员